Roche Q3 Report 2023

• Group sales grow by 1% at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter
• Excluding COVID-19 products, Group sales increase by 9%
• Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicines
• Diagnostics Division’s base business increases by 7%; overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022

Highlights in the third quarter of 2023:

• • EU approval of Evrysdi for babies under two months old with spinal muscular atrophy
  • First approval of subcutaneous form of cancer immunotherapy Tecentriq
  • Positive phase III data for Alecensa (early-stage lung cancer) and Ocrevus (subcutaneous injection; multiple sclerosis)
  • Positive phase II data for zilebesiran (hypertension in patients at high risk of cardiovascular disease) and additional positive phase II data for fenebrutinib (multiple sclerosis)
  • Positive longer-term efficacy and safety data for Ocrevus (multiple sclerosis) and Vabysmo (retinal vein occlusion, a severe eye disease)
  • Launch of first validated test for earlier diagnosis of neonatal sepsis and new module to improve laboratory efficiency